Regarding its involvement in sorafenib resistance, we previously demonstrated that miR-494 activates the AKT/mTOR pathway by targeting PTEN and reported a stronger antitumor effect of antagomiR-494 plus sorafenib treatment with respect to sorafenib alone in the DEN-HCC rat model [59]. This evidence concerns the gene MTOR and hepatocellular carcinoma.